ExternalDataReference
Type of Participant
01) NIH grant review panels will understand Phase II adaptive clinical trial designs.
02) NIH grant review panels will accept as valid Phase II adaptive clinical trial designs.
03) NIH grant review panels will understand Phase III adaptive clinical trial designs.
04) NIH grant review panels will accept as valid Phase III adaptive clinical trial designs.
05) The FDA will understand adaptive clinical trial designs relative to regulatory approval.
06) The FDA will accept as valid adaptive clinical trial designs relative to regulatory approval.
07) Researchers will understand adaptive clinical trial designs.
08) Researchers will accept as valid adaptive clinical trial designs.
09) Journal peer reviewers will understand adaptive clinical trial designs.
10) Journal peer reviewers will accept as valid adaptive clinical trial designs.
11) Clinicians will understand adaptive clinical trial designs.
12) Clinicians will accept as valid adaptive clinical trial designs.
13) Adaptive clinical trial designs pose ethical advantages from the patients' perspective.
14) Adaptive clinical trial designs pose ethical disadvantages from the patients' perspective.
15) Adaptive clinical trial designs pose ethical advantages from the researchers’perspective.
16) Adaptive clinical trial designs pose ethical disadvantages from the researchers’perspective.
17) Adaptive clinical trial designs pose ethical advantages from the societal perspective.
18) Adaptive clinical trial designs pose ethical disadvantages from the societal perspective.
19) Adaptive clinical trial designs increase the overall efficiency of research.
20) Adaptive clinical trial produce scientifically valid results.
21) Adaptive clinical trials will improve patient care faster than traditional trials.
Please use this space to elaborate on any responses from above.
1) NIH grant review panels will understand Phase II adaptive clinical trial designs.
2) NIH grant review panels will accept as valid Phase II adaptive clinical trial designs.
3) NIH grant review panels will understand Phase III adaptive clinical trial designs.
4) NIH grant review panels will accept as valid Phase III adaptive clinical trial designs.
5) The FDA will understand adaptive clinical trial designs relative to regulatory approval.
6) The FDA will accept as valid adaptive clinical trial designs relative to regulatory approval.
7) Researchers will understand adaptive clinical trial designs.
8) Researchers will accept as valid adaptive clinical trial designs.
9) Journal peer reviewers will understand adaptive clinical trial designs.
13) Adaptive clinical trial designs pose ethical advantages from the patients’perspective.
14) Adaptive clinical trial designs pose ethical disadvantages from the patients’perspective.
Which Survey
Please provide any comments regarding NIH and FDA responses to adaptive clinical trial designs.
Please provide any comments regarding researcher, peer-reviewer and clinician responses to adaptiv...
Please provide any comments regarding ethical aspects of adaptive clinical trial designs.
Please provide any comments regarding efficiency, validity, and translation into practice of adapt...